Introduction: Who Should Undergo Diagnostics

Prolymphocytic leukaemia is a rare and aggressive blood cancer that requires prompt diagnosis. People who should consider seeking diagnostic testing include those experiencing persistent and unexplained symptoms such as ongoing fatigue, night sweats that drench clothing or bedding, or unintentional weight loss over a short period. If you notice abdominal discomfort or a feeling of fullness in the upper left part of your belly, this could be a sign of an enlarged spleen, which is common in this condition.^[1]

Since prolymphocytic leukaemia primarily affects older adults, particularly those in their 60s, anyone in this age group experiencing these symptoms should consult their doctor without delay. The disease can present differently depending on whether it affects B cells or T cells. For instance, people with T-cell prolymphocytic leukaemia (T-PLL) may notice swollen lymph nodes in the neck, armpits, or groin, as well as skin changes like rashes or unusual lesions. In contrast, B-cell prolymphocytic leukaemia (B-PLL) typically does not involve the lymph nodes or skin as prominently.^[1]

Sometimes, prolymphocytic leukaemia is discovered accidentally during routine blood work for an unrelated health issue. A doctor might notice unusually high numbers of white blood cells or low counts of red blood cells and platelets. These findings often prompt further investigation. It is important to understand that while some people have noticeable symptoms, others may feel relatively well initially, especially in the early stages of B-PLL. However, because this type of leukaemia progresses rapidly, any suspicious findings should be evaluated thoroughly and quickly.^[3]

People with certain genetic conditions, such as ataxia telangiectasia (a disorder affecting movement and the immune system), have a higher risk of developing T-cell prolymphocytic leukaemia and may develop it at a younger age. If you have this condition or a family history of blood cancers, discussing regular monitoring with your healthcare provider is advisable.^[2][3]

Diagnostic Methods for Identifying the Disease

Diagnosing prolymphocytic leukaemia involves several steps, starting with blood tests and often progressing to more detailed examinations of bone marrow and genetic material within the abnormal cells. The goal is not only to confirm that leukaemia is present but also to identify the specific type and understand how aggressive it is.

Blood Tests

The first and most essential diagnostic tool is a complete blood count (CBC), which measures the numbers of red blood cells, white blood cells, and platelets in your blood. In prolymphocytic leukaemia, doctors typically find a very high white blood cell count. What makes this disease distinctive is the presence of large numbers of abnormal white blood cells called prolymphocytes. For a diagnosis of B-PLL, more than 55 percent of the lymphocytes circulating in the blood must be prolymphocytes. This high percentage is a defining characteristic that helps distinguish B-PLL from other similar blood cancers like chronic lymphocytic leukaemia (CLL).^[1][11]

Blood samples are also examined under a microscope to look at the size, shape, and features of the cells. Prolymphocytes are medium-sized cells with a distinctive appearance. They have a visible structure inside the nucleus called a nucleolus, which stands out when viewed under a microscope. In some cases, the cells may have small projections or blebs on their surface. Recognizing these features helps pathologists identify the disease accurately.^[4]

In addition to counting cells, blood tests check for anaemia (low red blood cell count) and thrombocytopenia (low platelet count). These findings occur because the rapidly multiplying abnormal cells crowd out the healthy cells in the bone marrow, leaving less room for normal blood cell production. Patients often feel tired and weak due to anaemia, and they may bruise or bleed easily because of low platelets.^[1][3]

Bone Marrow Tests

Sometimes, blood tests alone are not enough to confirm the diagnosis or to assess how extensively the leukaemia has affected the body. In such cases, doctors perform a bone marrow biopsy. This procedure involves inserting a needle into a large bone, usually the hip bone, to remove a small sample of bone marrow. The sample is then examined under a microscope to see how many prolymphocytes are present and whether they have replaced the normal bone marrow cells.^[3]

Bone marrow involvement in prolymphocytic leukaemia is typically diffuse, meaning the abnormal cells are spread throughout the marrow rather than clustered in specific areas. The cells found in the bone marrow have the same distinctive features as those seen in the blood. This consistency helps confirm the diagnosis.^[4]

Immunophenotyping

A critical part of diagnosing prolymphocytic leukaemia is determining whether the abnormal cells are B cells or T cells, as this distinction affects treatment decisions and prognosis. This is done through a technique called immunophenotyping, which uses special markers to identify proteins on the surface of the cells. These proteins act like identification tags, revealing the cell’s origin and type.^[4]

In T-cell prolymphocytic leukaemia, the cells typically show markers such as CD2, CD3, CD5, and CD7, indicating they are mature T cells. Most commonly, the cells are CD4 positive and CD8 negative, but in some cases, they may be positive for both markers or negative for both. Importantly, T-PLL cells do not show markers like TdT and CD1a, which are present in immature T cells. This confirms that the leukaemia arises from mature, rather than immature, T cells.^[2][4][7]

In B-cell prolymphocytic leukaemia, the cells express B-cell markers and can be distinguished from other B-cell cancers by their specific pattern of protein expression. This detailed analysis is essential because B-PLL shares features with other conditions like chronic lymphocytic leukaemia and mantle cell lymphoma, and accurate identification ensures the correct treatment approach.^[1]

Genetic and Chromosomal Testing

Understanding the genetic changes within the leukaemia cells provides important information about the disease’s behavior and how it might respond to treatment. Prolymphocytic leukaemia is associated with specific genetic abnormalities, and identifying these can help doctors predict the course of the disease.

In T-cell prolymphocytic leukaemia, the most common genetic abnormality is an inversion of chromosome 14, written as inv(14)(q11;q32), which occurs in about 80 percent of cases. In another 10 percent, there is a translocation involving chromosome 14. These changes affect genes that normally regulate cell growth and division, causing them to become overactive and drive the uncontrolled growth of leukaemia cells.^[4]

Abnormalities of chromosome 8 are also frequently found in T-PLL, occurring in about 75 percent of patients. These include changes like trisomy 8 (an extra copy of chromosome 8) or other rearrangements. Additionally, mutations in the ATM gene, located on chromosome 11, are present in 80 to 90 percent of T-PLL cases. The ATM gene normally helps repair damaged DNA, so when it is mutated, cells lose this protective function, increasing the risk of cancer.^[2][4]

Whole-genome and whole-exome sequencing, advanced techniques that read the entire genetic code of the leukaemia cells, have identified additional mutations in genes such as IL2RG, JAK1, JAK3, STAT5B, EZH2, FBXW10, and CHEK2. These discoveries are helping researchers understand the disease better and develop new targeted treatments.^[2]

In B-cell prolymphocytic leukaemia, genetic testing often reveals mutations in the TP53 gene (found in about 50 percent of cases) and the MYC gene (also found in about 50 percent). Some patients have both mutations, while others have neither. A deletion in part of chromosome 13 is found in about one in four people with B-PLL. These genetic changes contribute to the rapid growth and division of cancer cells.^[15]

Imaging and Physical Examination

Physical examination is an important part of the diagnostic process. Doctors will carefully feel the abdomen to check for an enlarged spleen or liver, both of which are common in prolymphocytic leukaemia. An enlarged spleen, called splenomegaly, is a defining feature of B-PLL and is also frequently present in T-PLL. Doctors may also check for swollen lymph nodes in the neck, underarms, and groin, particularly in T-PLL, where lymph node involvement is more common.^[1][3]

Imaging tests such as ultrasound or computed tomography (CT) scans may be used to measure the size of the spleen and liver more precisely and to assess whether the leukaemia has spread to other organs. These scans provide detailed pictures of the internal organs and can reveal abnormalities that are not apparent during a physical exam.^[3]

In T-PLL, skin involvement occurs in about 20 percent of cases. Doctors will examine the skin for rashes, lesions, or unusual discoloration. If skin lesions are present, a small sample may be taken for biopsy to confirm that they contain leukaemia cells. The infiltrates in the skin are typically dense and located in the deeper layer called the dermis.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to manage diseases. For patients with prolymphocytic leukaemia, participating in a clinical trial may offer access to innovative therapies that are not yet widely available. However, enrolling in a trial requires meeting specific criteria, and diagnostic tests play a central role in determining eligibility.

Confirming the Diagnosis and Disease Activity

Before a patient can join a clinical trial for prolymphocytic leukaemia, the diagnosis must be firmly established using the standard methods described earlier, including blood tests, bone marrow examination, immunophenotyping, and genetic testing. Trial protocols often require documentation showing that more than 55 percent of circulating lymphocytes are prolymphocytes in B-PLL or that the cells express the characteristic markers for T-PLL.^[1][2]

Another important factor is whether the disease is considered “active.” Between 20 and 30 percent of patients with T-PLL initially present with inactive disease, meaning they have fewer symptoms and the disease is progressing more slowly. However, these cases almost always progress to an active state within two years. Active disease is typically defined by symptoms such as significant weight loss, severe night sweats, fevers, or rapidly increasing white blood cell counts. Most clinical trials enroll only patients with active disease because inactive disease may not require immediate treatment, and the goal of the trial is often to test therapies that can control or slow active leukaemia.^[2]

Assessing Overall Health and Organ Function

Clinical trials have strict requirements to ensure patient safety. Doctors assess overall health status, often using a scoring system that measures how well a person can carry out daily activities. People who are very ill or have other serious health conditions may not be eligible for certain trials because the experimental treatments could pose additional risks.

Blood tests are used to evaluate the function of vital organs such as the liver and kidneys. This is important because some treatments are processed by the liver or eliminated by the kidneys, and impaired organ function could lead to dangerous side effects. Tests such as serum creatinine and liver enzyme levels provide this information.^[2]

Genetic Profiling for Targeted Therapies

As researchers learn more about the genetic mutations that drive prolymphocytic leukaemia, they are developing treatments that target specific abnormalities within the cancer cells. Some clinical trials are designed to test these targeted therapies, and enrollment may be restricted to patients whose leukaemia cells have the specific genetic change that the treatment is designed to address.

For example, mutations in genes involved in cell growth signaling pathways, such as JAK1, JAK3, and STAT5B, are being studied as targets for new drugs. Patients whose leukaemia cells have these mutations may be eligible for trials testing inhibitors of these pathways. Similarly, because TP53 mutations are common in B-PLL and are associated with resistance to standard chemotherapy, trials may specifically enroll patients with these mutations to test novel approaches that can overcome this resistance.^[2][10]

Advanced genetic testing, including whole-genome sequencing or next-generation sequencing, is often required as part of the screening process for these trials. These tests provide a comprehensive picture of all the genetic changes present in the leukaemia cells, helping to match patients with the most appropriate trial.^[2]

Monitoring Response to Treatment

For patients already enrolled in a clinical trial, ongoing diagnostic tests are used to monitor how well the treatment is working. Blood tests and bone marrow biopsies are repeated at regular intervals to measure changes in the number of prolymphocytes and to assess whether the leukaemia is shrinking or growing. A complete response means that no leukaemia cells can be detected in the blood or bone marrow, while a partial response means the number of leukaemia cells has decreased significantly but not disappeared entirely.^[2][10]

Imaging scans may also be repeated to check whether the spleen and liver have returned to normal size or whether swollen lymph nodes have shrunk. These measurements help researchers evaluate the effectiveness of the experimental treatment and determine whether it should be made more widely available.^[10]